Management of Nausea and Vomiting Chemotherapy-induced in Normandy
- Conditions
- CancerNauseaVomiting
- Registration Number
- NCT01440465
- Lead Sponsor
- Centre Francois Baclesse
- Brief Summary
The objective of this study was to evaluate the various parameters involved in the occurrence of nausea / vomiting during the first cycle of chemotherapy for solid tumors or hematologic among a group of chemotherapy-naive patients, despite anti standardized-emetics protocols.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- Aged over 18 years
- With solid tumors or hematologic in first line chemotherapy, administered intravenously,
- Able to understand the meaning of the questions
- Having given their written consent to participate in the survey.
This does not concern patients who:
- Do not give their consent for participation
- Do not speak French
- Suffer from cognitive deficits
- Are under therapy
- Must receive a combination of radio-chemotherapy
- Present an occlusive syndrome
- Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s)
- Have been previously treated with chemotherapy
- Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors
- Pregnant or breastfeeding.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method acute nausea and vomiting 2 years acute nausea and vomiting and / or delayed measured by the tool of anti emetic MAT MASCC.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Centre de la Baie
π«π·Avranches, France
Centre hospitalier
π«π·Bayeux, France
Centre FranΓ§ois Baclesse
π«π·Caen, France
Centre Jacques Monod
π«π·Flers, France
Centre Maurice Tubiana
π«π·Caen, France
Centre hospitalier public du cotentin
π«π·Cherbourg-Octeville, France